The story begins in the muscle fiber itself. During exercise, a transcriptional co-activator called PGC-1α, the master regulator of mitochondrial biogenesis, is activated in skeletal muscle through well-characterized energy-sensing pathways, including AMPK and SIRT1. PGC-1α drives expression of fibronectin domain-containing protein 5, or FNDC5, a membrane protein that is subsequently cleaved to release irisin into the circulation. This PGC-1α/FNDC5/irisin cascade was first described by Bruce Spiegelman’s group in 2012, when irisin was identified as the myokine responsible for driving brown-fat-like thermogenesis in white adipose tissue. Since then, studies have shown that irisin release scales with exercise intensity, occurs independently of age or fitness level, and can be detected in human cerebrospinal fluid by tandem mass spectrometry, a finding that strongly suggests the hormone does not remain confined to the periphery.

How, then, does a peptide secreted by leg muscles influence neurons deep inside the hippocampus? The review highlights recent work pointing to the blood–brain barrier as the critical checkpoint. Endothelial cells lining the brain’s vasculature express integrin receptors, and the αVβ5 integrin in particular has been identified as a binding partner for irisin. Research published in Molecular Neurobiology in 2025 demonstrated that the endothelial αV/β5 integrin signaling pathway plays a critical role in promoting irisin-induced expression of brain-derived neurotrophic factor, or BDNF, in the hippocampus. In other words, circulating irisin appears to engage integrin receptors on the barrier’s endothelial surface, triggering intracellular signaling that ultimately raises BDNF levels in brain tissue. Structural studies have shown that irisin forms a distinctive fibronectin type III dimer with a novel intersubunit beta-sheet, and more recent work indicates that irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α, adding molecular texture to how the hormone is recognized at the cell surface.

Once inside or at the brain’s doorstep, irisin’s principal downstream effector is BDNF, a neurotrophin long regarded as a cornerstone of synaptic plasticity, learning, and memory. The canonical 2013 study by Christiane Wrann and colleagues showed that exercise induces hippocampal BDNF through the PGC-1α/FNDC5 pathway, and subsequent genetic work established irisin as a critical regulator of cognitive function in mice. BDNF exerts its effects by binding the tropomyosin receptor kinase B, TrkB, a receptor tyrosine kinase that activates intracellular cascades including MAPK/ERK, PI3K/Akt, and PLCγ. Through these pathways, BDNF promotes dendritic growth, spine formation, long-term potentiation, and the activity of CaMKII, the central molecular organizer of synaptic plasticity. It also modulates NMDA receptor-dependent signaling through scaffolding proteins such as Girdin, linking neurotrophin support directly to the glutamatergic machinery of memory.

What makes the new review particularly compelling is its systematic mapping of BDNF’s protective actions onto each of the core pathological hallmarks of Alzheimer’s disease. First, BDNF enhances neuroplasticity, countering the synapse loss that correlates most strongly with cognitive decline. Second, it reduces amyloid-beta burden: exercise and BDNF have been shown to lower amyloid-beta production by enhancing alpha-secretase processing of the amyloid precursor protein, and irisin itself was recently shown to reduce amyloid-beta by inducing the release of the degrading enzyme neprilysin from astrocytes following downregulation of ERK–STAT3 signaling. Third, BDNF signaling restrains tau hyperphosphorylation, in part through modulation of glycogen synthase kinase 3, the kinase whose dysregulation drives pathological tau accumulation. Fourth, the axis dampens neuroinflammation, with aerobic exercise shown to attenuate glial activation and inflammatory signaling in experimental models. In a landmark 2019 study in Nature Medicine, exercise-linked FNDC5/irisin rescued synaptic plasticity and memory defects in Alzheimer’s mouse models, and a 2018 Science paper demonstrated that combined adult neurogenesis and BDNF can mimic exercise effects on cognition in an Alzheimer’s mouse model.

The review does not, however, paint an unconditionally rosy picture. It emphasizes that Alzheimer’s pathology feeds back negatively on the very axis that protects against it. Oxidative stress and mitochondrial dysfunction, both central features of the diseased brain, impair PGC-1α activity, suppress FNDC5 and BDNF expression, and weaken TrkB signaling, thereby creating a vicious cycle in which neurodegeneration erodes the endogenous defense system that would otherwise restrain it. Amyloid-beta oligomers, for instance, interfere with nuclear calcium signals and neuroprotective gene expression in hippocampal neurons, while mitochondrial damage in neural progenitors compromises the energy supply needed to sustain trophic signaling. This bidirectional framing, in which peripheral activation supports central protection but central pathology undermines the axis, transforms the irisin–BDNF system from a simple one-way messenger route into a dynamic feedback circuit whose integrity may itself determine disease trajectory.

From this molecular map, the authors derive a three-tiered translational strategy. Upstream, exercise remains the most physiological intervention, and the review notes that high-intensity exercise elicits greater irisin responses than low-intensity exercise under comparable energy expenditure, informing prescription design. Midstream, the barrier itself becomes a target: engineered blood–brain barrier-crossing peptides, such as those recently described in materials science literature, could enhance delivery of irisin-mimetic or BDNF-boosting agents into the central nervous system. Downstream, small-molecule TrkB agonists offer a way to bypass the hormone entirely. The flavonoid 7,8-dihydroxyflavone, a selective TrkB agonist discovered in 2010, has been shown to prevent synaptic loss and memory deficits in a mouse model of Alzheimer’s disease, and newer agonists such as R13 have demonstrated neuroprotective effects on mitochondrial function in 5×FAD mice. Together, these three intervention points, muscle, barrier, and receptor, define a pipeline for translating the muscle–brain dialogue into clinical practice.

The clinical stakes are enormous. Alzheimer’s disease and related dementias affect tens of millions of people worldwide, and the Global Burden of Disease study projects that prevalence will more than triple by mid-century as populations age. Existing amyloid-targeting therapies provide only modest benefit and come at high cost, which has intensified interest in mechanisms that act upstream or in parallel with amyloid. The irisin–BDNF axis is attractive precisely because it is multi-target: a single physiological signal simultaneously supports plasticity, curbs amyloid, restrains tau pathology, and calms inflammation. It is also supported by converging evidence across disorders, with recent work showing neuroprotective effects of irisin in mouse models of multiple sclerosis, cerebral ischemia, and Parkinson’s disease, suggesting the axis is a general-purpose mediator of exercise-induced brain resilience rather than an Alzheimer’s-specific curiosity.

Important caveats remain. Human irisin biology has historically been complicated by antibody reliability and the low abundance of the hormone, and the precise contribution of peripherally secreted versus centrally produced irisin to hippocampal BDNF induction is still being resolved. Whether boosting the axis in humans will slow cognitive decline in established disease, or only in preclinical stages, awaits intervention trials. Nevertheless, by assembling the complete molecular cascade, from PGC-1α activation in exercising muscle, through FNDC5 cleavage and integrin-mediated barrier engagement, to BDNF release and TrkB signaling in the hippocampus, the review provides a testable framework. It suggests that the old advice to keep moving is not merely generic wellness guidance but a quantifiable molecular prescription, and that pharmacologically reproducing the muscle–brain dialogue may one day offer a preventive strategy against one of medicine’s most feared diseases.

Subject of Research: The irisin–BDNF molecular axis mediating exercise-induced muscle–brain communication and neuroprotection in Alzheimer's disease

Article Title: Irisin-BDNF axis mediates muscle-brain communication: a complete molecular cascade and potential bidirectional feedback from peripheral activation to central protection

Article References: Irisin-BDNF axis mediates muscle-brain communication: a complete molecular cascade and potential bidirectional feedback from peripheral activation to central protection. (n.d.). https://doi.org/10.1007/s10522-026-10510-4

Image Credits: AI Generated

DOI: 10.1007/s10522-026-10510-4

Keywords: irisin, BDNF, Alzheimer's disease, FNDC5, PGC-1α, TrkB, blood-brain barrier, myokine, exercise, neuroprotection, synaptic plasticity, muscle-brain axis

Aging, the authors emphasize, is not a single number. Chronological age tells us little about how quickly any one tissue or organ system is deteriorating, which is why researchers have increasingly turned to organ-specific “biological clocks.” Epigenetic clocks, which estimate biological age from patterns of DNA methylation, have dominated this field. But muscles—the largest organ in the body and the engine of functional autonomy—follow their own nonlinear trajectory, heavily influenced by lifestyle, nutrition, and physical activity. To capture this, the research team, led by Federico Frasca, Chiara Pappalettera, Alessia Cacciotti, and Fabrizio Vecchio of the Brain Connectivity Laboratory at IRCCS San Raffaele in Rome, together with colleagues at the University of Sassari, employed a previously developed “muscle phenotypic clock.” This regression-based model quantifies muscle age (MA) from the battery of functional assessments recommended by the revised European consensus on sarcopenia, EWGSOP-2, including anthropometric estimates of muscle mass, measurements of muscle strength, and motor performance tests such as gait and mobility evaluations.

The key derived quantity is muscle age acceleration (MAA)—the difference between a person’s estimated muscle age and their chronological age. A negative value signals decelerated muscle aging, meaning muscles functionally younger than expected; a positive value signals accelerated aging, a potential early warning sign on the road to sarcopenia, the age-related loss of muscle mass and function that affects a growing share of the world’s aging population. In the new study, participants—all healthy, neurologically intact older adults screened for cognitive impairment and other exclusion criteria—were stratified into three groups based on their MAA: decelerated, normal, and accelerated muscle aging.

To probe the brain side of the equation, each participant underwent eyes-closed resting-state EEG, a century-old technique whose spontaneous rhythms have proven remarkably informative about network-level brain health. The researchers computed magnitude-squared coherence (MSCoh), a frequency-resolved measure of how strongly oscillatory activity at pairs of cortical regions fluctuates in tandem, effectively an index of functional connectivity between brain areas. They then applied graph-theoretical analysis, computing node strength—the sum of a node’s connectivity weights across the whole network—to identify which cortical regions carried the largest differences between muscle-aging groups. Statistical testing used nonparametric permutation-based procedures of the kind standard in modern EEG network science, guarding against spurious findings across the many electrodes, frequency bands, and pairwise comparisons involved.

The results were striking in both direction and topography. Participants with decelerated muscle aging—those with the biologically youngest muscles—showed significantly lower coherence than both the normal and accelerated groups in the Alpha 1 (roughly 8–10 Hz), Alpha 2 (10–12 Hz), and Beta 1 (13–20 Hz) frequency bands. In other words, the parietal and frontal networks that generate these rhythms were less tightly synchronized in people whose muscles were aging slowly. Alpha oscillations are classically associated with the brain’s attentional gating and the efficient allocation of cognitive resources, while beta rhythms are deeply involved in sensorimotor control and the maintenance of the motor status quo; both bands are known to be altered in dementia and in normal aging, where coherence typically increases, a pattern interpreted by many groups as a sign of reduced neural flexibility or compensatory neural “crosstalk.”

The node strength analysis sharpened the picture further. The decelerated MA group showed lower node strength in the right frontal area across the Alpha 1, Beta 1, and Beta 2 bands, while the normal MA group showed lower values in the right temporal region compared with the accelerated MA group. The consistent involvement of right-hemispheric frontal and temporal hubs is noteworthy. Right frontal regions are central to attentional control and executive function, and their connectivity patterns change in characteristic ways with aging and neurodegeneration. The findings align with established models of age-related network reorganization, such as the HAROLD model of hemispheric asymmetry reduction, in which older adults recruit additional homotopic regions to sustain performance. In this framework, the increased synchronization seen in people with accelerated muscle aging may represent a less efficient, more rigid network configuration—perhaps an early neural correlate of the same processes that stiffen muscles and slow gait.

What mechanism could connect the biological age of muscle to the topology of brain networks? The authors and the broader literature point to several converging pathways. Skeletal muscle is not merely a mechanical engine; it is an endocrine organ that secretes myokines during contraction, molecules such as irisin and interleukin-6 variants that influence neuroplasticity, inflammation, and metabolism. Conversely, the corticospinal drive from the motor cortex shapes the very muscle activity that maintains muscle mass, and recent work has suggested that deteriorating corticospinal control may itself be a determinant of sarcopenia. Chronic low-grade inflammation—termed “inflammaging”—is a shared driver of both muscle wasting and cognitive decline, and clinical studies have repeatedly linked sarcopenia to white matter hyperintensities, cognitive impairment, and dementia risk. The new study is distinctive in that it avoids the confounding presence of diagnosed disease: all participants were healthy, meaning the brain-network differences reflect a graded, subclinical gradient of body-brain aging within the normal older population.

Methodologically, the study is notable for its attempt to quantify an organ’s biological age using purely phenotypic, clinically accessible measures. The muscle phenotypic clock, developed by the Sassari group in earlier cross-sectional work on middle-aged and older adults, was built with regularized regression techniques—the elastic net of Zou and Hastie, implemented in machine-learning toolchains such as scikit-learn—combining anthropometrics, bioelectrical estimates of skeletal muscle mass, grip strength and other strength measures, and standardized motor tests including the timed Up-and-Go and the six-minute walk protocol. Because these measures can be gathered in any geriatric clinic, the approach sidesteps the cost and invasiveness of epigenetic sequencing, raising the prospect that a routine functional assessment could one day yield both a muscle age score and, if corroborated by future work, a noninvasive window into brain network health.

The clinical implications cut in both directions. First, MAA could serve as a low-cost screening variable that flags older adults whose brain networks may already be drifting toward the hyper-synchronous patterns associated with cognitive vulnerability, well before symptoms appear. Second, and perhaps more provocatively, the findings suggest that interventions designed to slow muscle aging—progressive resistance training, adequate protein intake, physical activity programs—might do double duty by favorably reshaping brain connectivity. Previous EEG studies have shown that resting-state connectivity predicts motor skill learning and responds to rehabilitation after stroke, and integrated motor-cognitive training programs are increasingly advocated for frail older adults. If muscle age acceleration truly shapes brain network topography, then redirecting that trajectory becomes not merely a matter of preserving mobility but of protecting the brain itself.

The authors are careful to frame the study as hypothesis-generating. It is cross-sectional, so causality cannot be established: accelerated muscle aging might drive brain changes, brain changes might drive muscle decline, or a third factor such as systemic inflammation might drive both. The cohort, while carefully characterized, is limited in size, and EEG coherence reflects only cortical, predominantly radial, current sources rather than the full three-dimensional complexity of brain network dynamics. Longitudinal studies tracking MAA and EEG networks in the same individuals over years, ideally combined with measures of cognitive trajectory and blood-based biomarkers, will be needed to determine whether the muscle clock can predict future brain decline and whether interventions that decelerate muscle aging produce measurable, beneficial shifts in resting-state connectivity.

Even with those caveats, the study lands at a moment of intense interest in biological age clocks and in the muscle–brain axis. The idea that “muscle age” is not just a poetic phrase but a quantifiable, clinically meaningful variable—one that leaves an electrical signature in the resting brain—is likely to energize both the geroscience and neurorehabilitation communities. For a global population aging at unprecedented speed, the promise of a single clinic visit that yields a muscle age, an early read on brain network health, and a personalized prescription of exercise and nutrition is an alluring one. This study offers the first EEG-based evidence that the trajectory of muscle aging and the architecture of resting brain networks are systematically intertwined in healthy older people, and it points toward an era in which keeping the body’s largest organ young may be among the most effective strategies for keeping the brain young too.